CARYN RESNICK, FNP-C
Oncology Clinical Nurse Specialist in PARIS, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
CARYN RESNICK, FNP-C reported a CMS MIPS final score of 89.4449/100 — above the 83.1 national average — and filed 640 Medicare Part D claims in 2023.
- 89.4449/100
- MIPS score · +6 vs avg
- 640
- Part D claims, 2023
- 94%
- generic prescribing
- $663.18
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
CARYN RESNICK, FNP-C's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
89 Top 42% higher than 58% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
What does the federal data show about CARYN RESNICK, FNP-C?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Texas
How Oncology Clinical Nurse Specialist compares to other specialties among Texas providers
Oncology Clinical Nurse Specialist share within Texas
Oncology Clinical Nurse Specialist is one of the more visible NUCC categories in Texas
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
CARYN RESNICK, FNP-C's 2023 MIPS final score plotted against the Oncology Clinical Nurse Specialist national average
- MIPS Final Score
- 89.4449/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Oncology Clinical Nurse Specialist) — 89.4449/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Oncology Clinical Nurse Specialist US NPIs
89.4449/100 MIPS final score — 6.3 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Oncology Clinical Nurse Specialist. Quality dim: 75.8575.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
CARYN RESNICK, FNP-C appears in the CMS NPPES registry as a Oncology Clinical Nurse Specialist provider holding FNP-C credentials at 3550 NE LOOP 286, PARIS, TX, 75460, with a listed phone of (903) 737-4515. NPI 1356817357 was issued on 10/17/2018. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what RESNICK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 640 prescription claims written by this provider, covering 213 Medicare beneficiaries and totaling roughly $72K in drug spend, split 6% brand-name and 94% generic by claim count, with an opioid prescribing rate of 2.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 89.4449/100 for the 2023 performance year (Quality 75.8575), compared with the national average of 83.1.
Oncology Clinical Nurse Specialist is a narrow specialty nationwide, with 209 enrolled providers across 38 states and an average of 435 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1356817357 |
|---|---|
| Specialty | Oncology Clinical Nurse Specialist |
| Credentials | FNP-C |
| Gender | Female |
| NPI Issued | 10/17/2018 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm CARYN RESNICK, FNP-C's current license status, disciplinary history, and board certifications with the Texas Medical Board in Texas before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for CARYN RESNICK, FNP-C. Source: openpaymentsdata.cms.gov.
Total received
$663
Largest payer
Lilly USA, LLC
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Texas TMB 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to CARYN RESNICK, FNP-C. To verify CARYN RESNICK, FNP-C's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
6% brand-name claims vs 94% generic, on 640 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 730
- Total Day Supply
- 13,833
- Brand vs Generic
- 6% brand / 94% generic
- Brand Drug Cost
- $63K
- Generic Drug Cost
- $9K
- Opioid Claims
- 14 (2.2% rate)
- Antibiotic Claims
- 80
Patient Demographics
- Average Patient Age
- 71.9 years
- Avg HCC Risk Score
- 2.15
- Gender Split
- 53% female / 47% male
- Age Distribution
- <65: 32, 65-74: 95, 75-84: 71, 85+: 15
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What CARYN RESNICK, FNP-C prescribes most
Top Medicare Part D drugs by claim count, 2023
- Ondansetron Hcl
Ondansetron Hcl
133 claims
- Promethazine Hcl
Promethazine Hcl
86 claims
- Gabapentin 33
Gabapentin
33 claims
- Potassium Chloride 32
Potassium Chloride
32 claims
- Olanzapine 30
Olanzapine
30 claims
- Levofloxacin 26
Levofloxacin
26 claims
- Levothyroxine Sodium 22
Levothyroxine Sodium
22 claims
- Azithromycin 17
Azithromycin
17 claims
| Drug | Claims |
|---|---|
| Ondansetron Hcl | 133 |
| Promethazine Hcl | 86 |
| Gabapentin | 33 |
| Potassium Chloride | 32 |
| Olanzapine | 30 |
| Levofloxacin | 26 |
| Levothyroxine Sodium | 22 |
| Azithromycin | 17 |
| Prednisone | 17 |
| Cephalexin | 15 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Oncology Clinical Nurse Specialist Overview
How CARYN RESNICK, FNP-C fits within the Oncology Clinical Nurse Specialist landscape nationally.
CARYN RESNICK, FNP-C's 640 claims are above the specialty average of 435.
Nearby Oncology Clinical Nurse Specialist Providers in Texas
Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as RESNICK.
Compare Oncology Clinical Nurse Specialist nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Texas
Frequently Asked Questions
What is CARYN RESNICK, FNP-C's specialty? ▼
How much does CARYN RESNICK, FNP-C prescribe under Medicare Part D? ▼
What is CARYN RESNICK, FNP-C's Medicare quality score? ▼
Where is CARYN RESNICK, FNP-C located? ▼
What is CARYN RESNICK, FNP-C's NPI number? ▼
Does CARYN RESNICK, FNP-C prescribe more brand-name or generic drugs? ▼
Does CARYN RESNICK, FNP-C prescribe opioids? ▼
How many Oncology Clinical Nurse Specialist providers are there in the US? ▼
What drugs does CARYN RESNICK, FNP-C prescribe most often? ▼
Does CARYN RESNICK, FNP-C accept Medicare? ▼
How can I verify CARYN RESNICK, FNP-C's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology